Mathieu Burtnyk - Profound Medical Senior TULSAPRO
| PROF Stock | USD 7.55 0.03 0.40% |
Executive
Mathieu Burtnyk is Senior TULSAPRO of Profound Medical Corp
| Age | 42 |
| Address | 2400 Skymark Avenue, Mississauga, ON, Canada, L4W 5K5 |
| Phone | 647 476 1350 |
| Web | https://www.profoundmedical.com |
Profound Medical Management Efficiency
The company has return on total asset (ROA) of (0.4462) % which means that it has lost $0.4462 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9017) %, meaning that it created substantial loss on money invested by shareholders. Profound Medical's management efficiency ratios could be used to measure how well Profound Medical manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.69. The current Return On Capital Employed is estimated to decrease to -0.8. At this time, Profound Medical's Total Assets are most likely to increase significantly in the upcoming years. The Profound Medical's current Other Current Assets is estimated to increase to about 1.7 M, while Non Current Assets Total are projected to decrease to roughly 1.9 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Chris Williamson | Iradimed Co | N/A | |
| Lynn Neuhardt | Iradimed Co | N/A | |
| Craig Palmer | CVRx Inc | 47 | |
| Badri Amurthur | LivaNova PLC | N/A | |
| Andrew Hill | Paragon 28 | 40 | |
| Frank Vizesi | Orthofix Medical | N/A | |
| Meredith Vornholt | Nevro Corp | N/A | |
| Michael Pisetsky | Si Bone | 46 | |
| RN MBA | CVRx Inc | N/A | |
| Suzanne Armstrong | Orthofix Medical | N/A | |
| Jeff Bertolini | Si Bone | N/A | |
| Aimee Einstein | Si Bone | N/A | |
| Dylan John | Neuropace | N/A | |
| Kelley Nicholas | Neuropace | N/A | |
| John Manders | SurModics | 43 | |
| Sarah Huber | Pulmonx Corp | N/A | |
| Jeremy JD | Sight Sciences | 54 | |
| Shana MBA | Nevro Corp | 51 | |
| Jennifer Englund | CVRx Inc | N/A | |
| MSc MD | CVRx Inc | N/A | |
| Stephen JD | Sight Sciences | N/A | |
Management Performance
| Return On Equity | -0.9 | ||||
| Return On Asset | -0.45 |
Profound Medical Corp Leadership Team
Elected by the shareholders, the Profound Medical's board of directors comprises two types of representatives: Profound Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Profound. The board's role is to monitor Profound Medical's management team and ensure that shareholders' interests are well served. Profound Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Profound Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Arun MBA, Chairman CEO | ||
| Hartmut Warnken, Senior Alliances | ||
| Jacques Cornet, Senior Sonalleve | ||
| Stephen Kilmer, Investor Relations | ||
| Mathieu Burtnyk, Senior TULSAPRO | ||
| Thomas MBA, Chief Officer | ||
| Abbey Goodman, Chief Global | ||
| Levant Tinaz, Software Developer | ||
| Michael Mydra, VP Access | ||
| Rashed Dewan, Chief Officer |
Profound Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Profound Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.9 | ||||
| Return On Asset | -0.45 | ||||
| Operating Margin | (3.17) % | ||||
| Current Valuation | 165.29 M | ||||
| Shares Outstanding | 24.66 M | ||||
| Shares Owned By Insiders | 8.59 % | ||||
| Shares Owned By Institutions | 43.81 % | ||||
| Number Of Shares Shorted | 340.53 K | ||||
| Price To Book | 5.97 X | ||||
| Price To Sales | 20.72 X |
Currently Active Assets on Macroaxis
When determining whether Profound Medical Corp is a strong investment it is important to analyze Profound Medical's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Profound Medical's future performance. For an informed investment choice regarding Profound Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Profound Medical Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Profound Medical. If investors know Profound will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Profound Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.34) | Revenue Per Share 0.38 | Quarterly Revenue Growth 0.639 | Return On Assets (0.45) | Return On Equity (0.90) |
The market value of Profound Medical Corp is measured differently than its book value, which is the value of Profound that is recorded on the company's balance sheet. Investors also form their own opinion of Profound Medical's value that differs from its market value or its book value, called intrinsic value, which is Profound Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Profound Medical's market value can be influenced by many factors that don't directly affect Profound Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Profound Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Profound Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Profound Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.